Identification of mutations that cause rare familial forms of Parkinson's disease (PD) and
subsequent studies of genetic risk factors for sporadic PD have led to an improved …

Parkinson's disease (PD) is the second most common neurodegenerative disorder
characterized by progressive loss of dopaminergic neurons in the substantia nigra. The …

Among the more promising treatments proposed for Alzheimer's disease (AD) and
Parkinson's disease (PD) are those reducing brain insulin resistance. The antidiabetics in …

Neuroprotective strategies, including free radical scavengers, ion channel modulators, and
anti-inflammatory agents, have been extensively explored in the last 2 decades for the …

Although progress has been made in the symptomatic treatment of Parkinson's disease
since the discovery of L-dopa in the 1960s, no neuroprotective therapy is yet available …

Background Parkinson's disease (PD) is a neurodegenerative disorder involving the
degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) …

There is consensus that amelioration of the motor symptoms of Parkinson's disease is most
effective with l-DOPA (levodopa). However, this necessary therapeutic step is biased by an …

Introduction Diabetes is a risk factor for Parkinson's disease (PD) and shares similar
dysregulated insulin pathways. Glucagon-like peptide-1 (GLP-1) analogs originally …

Parkinson's disease (PD) is an incurable neurodegenerative disorder leading to progressive
motor impairment and for which there is no cure. From the first postmortem account …

Parkinson's disease (PD) is a neurodegenerative illness described as damage to
dopaminergic neurons. There is increasing evidence that neuroinflammatory activity …